KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial.

Wei-Hao Xie, Wei-Wei Xiao, Hui Chang, Ming-Jun Xu, Yong-Hong Hu, Tong-Chong Zhou, Qiong Zhong, Chun-Yan Chen, Li-Xia Lu, Qiao-Xuan Wang, Yu-Jia Zhu, Jing Yang, Xing-Yuan Shi, Hua-Long Kang, Jia-Wang Wei, Rong Huang, Hai-Hua Peng, Yan Yuan, Shi-Hai Wu, Xin-Hua Jiang, Ya-Jie Liu, Bi-Xiu Wen, Yuan-Hong Gao

BMJ 389 e081557

PMID40233976
PMCIDPMC11997745
DOI10.1136/bmj-2024-081557
发表日期2025-04-15
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:非 KM 图。
摘要

摘要

OBJECTIVE: To compare the effects of four cycles of docetaxel with cisplatin as a neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with concurrent chemoradiotherapy alone by assessing reductions in distant metastasis and improvements in survival in patients with stage N2-3nasopharyngeal carcinoma. DESIGN: Phase 3, multicentre, randomised controlled trial. SETTING: Six sites in China from 23 February 2016 to 18 February 2019. PARTICIPANTS: 186 participants aged ≤70 years with a diagnosis of untreated stage T1-4N2-3M0 nasopharyngeal carcinoma. INTERVENTION: Participants were prospectively enrolled and randomly allocated to either the neoadjuvant chemotherapy plus concurrent chemoradiotherapy group (four cycles of neoadjuvant chemotherapy (docetaxel 75 mg/m2 on day 1 and cisplatin 37.5 mg/m2 on days 2-3, every 3 weeks) followed by concurrent chemoradiotherapy (intensity modulated radiotherapy plus weekly cisplatin 40 mg/m2) or the concurrent chemoradiotherapy only group, in a 1:1 ratio. MAIN OUTCOME MEASURES: Five year distant metastasis-free survival and overall survival were analysed using the intention-to-treat approach. RESULTS: 93 participants were assigned to each of the neoadjuvant chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy only groups. After a median follow-up time of 76.9 (interquartile range 65.4-85.9) months, the neoadjuvant chemotherapy plus concurrent chemoradiotherapy group had superior five year distant metastasis-free survival (91.3% (95% confidence interval (CI) 85.4% to 97.2%) versus 78.2% (69.8% to 86.6%); hazard ratio 0.41 (95% CI 0.19 to 0.87); P=0.02) and five year overall survival (90.3% (84.2% to 96.4%) versus 82.6% (75.0% to 90.2%); hazard ratio 0.38 (0.18 to 0.82); P=0.01). Grade 3/4 acute toxicities were observed in 60 (65%) and 46 (51%) patients in the neoadjuvant chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy only groups, respectively (P=0.05). The higher acute toxicity observed in the neoadjuvant chemotherapy plus concurrent chemoradiotherapy group was primarily due to grade 3/4 neutropenia (43 (47%) v 10 (11%); P<0.001). No significant difference in any late toxicity was observed between the two groups, and participants in the neoadjuvant chemotherapy plus concurrent chemoradiotherapy group tended to have a better quality of life five years after enrolment. CONCLUSIONS: Four cycles of docetaxel plus cisplatin neoadjuvant chemotherapy with concurrent chemoradiotherapy can effectively reduce distant metastasis and improve survival for patients with stage N2-3 nasopharyngeal carcinoma with manageable toxicities. TRIAL REGISTRATION: ClinicalTrials.gov NCT02512315.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Flowchart of trial design. CCRT=concurrent chemoradiotherapy; NACT=neoadjuvant chemotherapy
非 KM Figure
Fig 2Kaplan-Meier survival curves in intention-to-treat (ITT) population. CCRT=concurrent chemoradiotherapy; CI=confidence interval; NACT=neoadjuvant chemotherapy
非 KM Figure